The global market for Alzheimer’s disease therapeutics could soar to $8 billion once therapies are approved that actually change the course of the disease. The current therapeutic market is valued at $3-4 billion and is shared among drugs that temporarily delay disease progression or address the symptoms but do not alter the underlying disease. Despite all the research on amyloid plaques and neurofibrillary tangles, there is still a debate on whether these biological phenomena are causative or symptomatic of Alzheimer’s. Once scientists can clearly and unequivocally define key factors related to the actual biology of the disease itself, therapeutic advances could take place much more quickly.
Genetic Engineering & Biotechnology News, August 2012